Abstract
The family of α2-adrenergic receptors (α2-ARs) comprises three subtypes which are each endowed with specific functions. α2-agonists and α2-antagonists are part of the clinician armamentarium since several decades; however, none of the compounds so far available is subtype selective. For long, clonidine and yohimbine have been used for the treatment of hypertension and impotence respectively, but both have been superseded by newer drugs. This review attempts, by a comprehensive analysis of the literature, to cover the present clinical use and the potential therapeutic interest of α2-agonists or antagonists. From the clinical data, it is concluded that, with the exception of a few particular situations, α2-agonists are only of limited utility as a monotherapy. By contrast, they offer several powerful advantages when used in adjunctive therapy. In perioperative settings, α2-agonists are extremely valuable adjuncts to anesthetics and analgesics for the induction of anxiolysis, maintenance of sedation, management of pain and prevention of shivering. In the ophthalmic clinic, they are used to lower intra-ocular pressure during laser surgery of the eye. As a daily medication, α2-agonists are also of interest for the treatment of glaucoma, muscle spasticity, opiate withdrawal, and behavior disorders. The a2-antagonists are useful antidotes for reversing the threatening effects of agonist overdose, but currently there are very few indications. New applications are under investigation, and new molecules with more refined subtypeselectivity may emerge, so the clinical utility of both α2-agonists and antagonists will undoubtedly expand in the future.
Keywords: Attention-deficit hyperactivity, Primary open-angle glaucoma, Hypertension, Withdrawal syndrome, Muscle Spasticity
Current Topics in Medicinal Chemistry
Title: Interest of α2-Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives
Volume: 7 Issue: 2
Author(s): Pierre-Antoine Crassous, Colette Denis, Herve Paris and Jean Michel Senard
Affiliation:
Keywords: Attention-deficit hyperactivity, Primary open-angle glaucoma, Hypertension, Withdrawal syndrome, Muscle Spasticity
Abstract: The family of α2-adrenergic receptors (α2-ARs) comprises three subtypes which are each endowed with specific functions. α2-agonists and α2-antagonists are part of the clinician armamentarium since several decades; however, none of the compounds so far available is subtype selective. For long, clonidine and yohimbine have been used for the treatment of hypertension and impotence respectively, but both have been superseded by newer drugs. This review attempts, by a comprehensive analysis of the literature, to cover the present clinical use and the potential therapeutic interest of α2-agonists or antagonists. From the clinical data, it is concluded that, with the exception of a few particular situations, α2-agonists are only of limited utility as a monotherapy. By contrast, they offer several powerful advantages when used in adjunctive therapy. In perioperative settings, α2-agonists are extremely valuable adjuncts to anesthetics and analgesics for the induction of anxiolysis, maintenance of sedation, management of pain and prevention of shivering. In the ophthalmic clinic, they are used to lower intra-ocular pressure during laser surgery of the eye. As a daily medication, α2-agonists are also of interest for the treatment of glaucoma, muscle spasticity, opiate withdrawal, and behavior disorders. The a2-antagonists are useful antidotes for reversing the threatening effects of agonist overdose, but currently there are very few indications. New applications are under investigation, and new molecules with more refined subtypeselectivity may emerge, so the clinical utility of both α2-agonists and antagonists will undoubtedly expand in the future.
Export Options
About this article
Cite this article as:
Crassous Pierre-Antoine, Denis Colette, Paris Herve and Senard Jean Michel, Interest of α2-Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives, Current Topics in Medicinal Chemistry 2007; 7 (2) . https://dx.doi.org/10.2174/156802607779318190
DOI https://dx.doi.org/10.2174/156802607779318190 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Disease and Dyslipidemia: Beyond LDL
Current Pharmaceutical Design Identification of Candidate Biomarkers of Acute Aortic Dissection
Recent Patents on DNA & Gene Sequences Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns?
Current Pharmaceutical Design Oleic Acid Vesicles for Transdermal Delivery of Propranolol Hydrochloride: Development and Characterization
Current Drug Therapy The Roles of Abnormal Renal Sodium Handling in Hypertension Associated with Metabolic Syndrome
Current Hypertension Reviews <i>In silico</i> Modeling of Antimalarial Protein Kinase Inhibitors
Letters in Drug Design & Discovery Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews Regioselective Synthesis of 2-Chloroquinoline Based Ethyl 4-(3- Hydroxyphenyl)-2,7,7-Trimethyl-5-Oxo-1,4,5,6,7,8-Hexahydroquinoline-3- Carboxylates and their In-Silico Evaluation Against P. falciparum Lactate Dehydrogenase
Medicinal Chemistry Design of Second Generation Phosphodiesterase 5 Inhibitors
Current Topics in Medicinal Chemistry Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
Cardiovascular & Hematological Agents in Medicinal Chemistry Angiogenesis and Microvasculature in the Female Reproductive Organs: Physiological and Pathological Implications
Current Pharmaceutical Design Recent Advances on Stearoyl-Coa Desaturase Regulation in Fatty Liver Diseases
Current Drug Metabolism Drug Repositioning Through Network Pharmacology
Current Topics in Medicinal Chemistry New Approved Medications for Idiopathic Pulmonary Fibrosis
Current Drug Therapy IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Idiopathic Pulmonary Fibrosis)
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) The Role of Neuropeptide Processing Enzymes in Endocrine (Prostate) Cancer: EC 3.4.24.15 (EP24.15)
Protein & Peptide Letters Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Neuropeptides and Gastric Mucosal Homeostasis
Current Topics in Medicinal Chemistry COPD Management: Look Beyond the Airway Obstruction, Chronic Bronchitis and Emphysema
Current Respiratory Medicine Reviews